| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2021 | BELLBROOK LABS LLC | 1232 FOURIER DR STE 115 | MADISON | WI | 53717-1960 | DANE | USA | R21AI160508 | Targeting a Human Acyltransferase for Broad-Spectrum Antivirals | 000 | 1 | NIH | 11/7/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $270,929 ) |
| | 2024 | 2024 | BELLBROOK LABS LLC | 1232 FOURIER DR STE 115 | MADISON | WI | 53717-1960 | DANE | USA | R43GM154542 | Chemically Induced Dimerization Systems for High Throughput Enzyme Assays | 000 | 1 | NIH | 9/20/2024 | $270,929 |
| | 2024 | 2022 | BELLBROOK LABS LLC | 1232 FOURIER DR STE 115 | MADISON | WI | 53717-1960 | DANE | USA | R44AI141281 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases | 000 | 3 | NIH | 4/24/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R21AI160508 | Targeting a Human Acyltransferase for Broad-Spectrum Antivirals | 000 | 1 | NIH | 6/30/2023 | $0 |
| | 2023 | 2020 | BELLBROOK LABS LLC | 5500 NOBEL DR | MADISON | WI | 53711-4951 | DANE | USA | R43CA254590 | Discovery of TREX1 Antagonists for Cancer Immunotherapy | 000 | 1 | NIH | 11/2/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $832,430 ) |
| | 2022 | 2022 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44AI141281 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases | 000 | 3 | NIH | 2/9/2022 | $832,430 |
| | 2022 | 2019 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43AI141281 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases | 000 | 1 | NIH | 11/4/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,379,340 ) |
| | 2021 | 2021 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R21AI160508 | Targeting a Human Acyltransferase for Broad-Spectrum Antivirals | 000 | 1 | NIH | 7/27/2021 | $390,500 |
| | 2021 | 2021 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44AI141281 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases | 000 | 2 | NIH | 2/11/2021 | $988,840 |
| | 2021 | 2020 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43CA254590 | Discovery of TREX1 Antagonists for Cancer Immunotherapy | 000 | 1 | NIH | 11/20/2020 | $0 |
| | 2021 | 2019 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43AI141281 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases | 000 | 1 | NIH | 2/11/2021 | $0 |
| | 2021 | 2019 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 000 | 3 | NIH | 8/8/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $300,000 ) |
| | 2020 | 2020 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43CA254590 | Discovery of TREX1 Antagonists for Cancer Immunotherapy | 000 | 1 | NIH | 9/11/2020 | $300,000 |
| | 2020 | 2017 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM109621 | Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery | 000 | 3 | NIH | 9/17/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,045,323 ) |
| | 2019 | 2019 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43AI141281 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases | 000 | 1 | NIH | 6/12/2019 | $300,000 |
| | 2019 | 2019 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 000 | 3 | NIH | 4/11/2019 | $416,339 |
| | 2019 | 2019 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 001 | 3 | NIH | 8/8/2019 | $328,984 |
| | 2019 | 2017 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM109621 | Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery | 000 | 3 | NIH | 4/26/2019 | $0 |
| | 2019 | 2016 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43AA025498 | Pharmacological Validation of GIV/Girdin, a Guanine Nucleotide Exchange Factor, for Liver Fibrosis | 000 | 1 | NIH | 12/21/2018 | $0 |
| | 2019 | 2016 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R41GM121123 | Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers | 000 | 1 | NIH | 7/12/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $591,712 ) |
| | 2018 | 2018 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 000 | 2 | NIH | 4/16/2018 | $591,712 |
| | 2018 | 2017 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 001 | 1 | NIH | 5/7/2018 | $0 |
| | 2018 | 2017 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 000 | 1 | NIH | 4/11/2018 | $0 |
| | 2018 | 2016 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R41GM121123 | Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers | 000 | 1 | NIH | 7/17/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $678,896 ) |
| | 2017 | 2017 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R44GM109621 | Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery | 000 | 3 | NIH | 4/24/2017 | $390,213 |
| | 2017 | 2017 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43GM123833 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer | 000 | 1 | NIH | 4/26/2017 | $288,683 |
| | 2017 | 2015 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R41NS090693 | Axonal Transport HTS Platform for Neurodegeneration Drug Discovery | 000 | 1 | NIH | 8/18/2017 | $0 |
| | 2017 | 2015 | BELLBROOK LABS, LLC | 5500 NOBEL DR STE 230 | MADISON | WI | 53711-4951 | DANE | USA | R43NS089394 | Fluorescent biosensors for dynamic monitoring of paracrine signaling in extracellular matrix | 000 | 1 | NIH | 4/14/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,058,731 ) |
| | 2016 | 2016 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R44GM109621 | Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery | 000 | 2 | NIH | 4/26/2016 | $470,463 |
| | 2016 | 2016 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R43AA025498 | Pharmacological Validation of GIV/Girdin, a Guanine Nucleotide Exchange Factor, for Liver Fibrosis | 000 | 1 | NIH | 9/19/2016 | $353,332 |
| | 2016 | 2016 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R41GM121123 | Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers | 000 | 1 | NIH | 9/13/2016 | $234,936 |
|
| Issue Date FY: 2015 ( Subtotal = $449,999 ) |
| | 2015 | 2015 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R41NS090693 | Axonal Transport HTS Platform for Neurodegeneration Drug Discovery | 000 | 1 | NIH | 5/6/2015 | $225,000 |
| | 2015 | 2015 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R43NS089394 | Fluorescent biosensors for dynamic monitoring of paracrine signaling in extracellular matrix | 000 | 1 | NIH | 3/31/2015 | $224,999 |
|
| Issue Date FY: 2014 ( Subtotal = $224,931 ) |
| | 2014 | 2014 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R43GM109621 | Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery | 001 | 1 | NIH | 7/17/2014 | $1,478 |
| | 2014 | 2014 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R43GM109621 | Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery | 000 | 1 | NIH | 7/4/2014 | $223,453 |
|
| Issue Date FY: 2013 ( Subtotal = $194,007 ) |
| | 2013 | 2013 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711-4951 | DANE | USA | R44HL103079 | SCREENING DEVICE FOR DIFFERENTIATED PRIMARY CELL MODELS OF AIRWAY EPITHELIA | 001 | 3 | NIH | 7/22/2013 | $194,007 |
| | 2013 | 2012 | BELLBROOK LABS LLC | 5500 NOBEL DRIVE SUITE 250 | MADISON | WI | 53711 | DANE | USA | R44HL103079 | SCREENING DEVICE FOR DIFFERENTIATED PRIMARY CELL MODELS OF AIRWAY EPITHELIA | 000 | 2 | NIH | 5/22/2013 | $0 |
|
|
